Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds: Results of a two-year, prospective trial

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 44, Issue 7, 1999, Pages 601-605

  Castelo Branco, Camil ^a,b   Pons, Francesca ^a   Vicente, Juan José ^a   Sanjuán, Alex ^a   Vanrell, Juan Antonio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Bone loss, postmenopausal; Bone mineral density; Ossein hydroxyapatite; Postmenopausal osteoporosis

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; DROLOXIFENE; FLUORIDE SODIUM; GROWTH HORMONE; HYDROXYAPATITE; RALOXIFENE; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE MASS; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN BLOOD LEVEL; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT PLANNING;

AGED; BONE DENSITY; CALCIUM CARBONATE; DURAPATITE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 0032800735     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Delmas P: The new definition of osteoporosis: Implications for diagnosis and treatment. In Menopause. Edited by M Birkhäuser, H Rozenbaum. Paris, ESKA, 1996, pp 97-105
2. Richelson LS, Wahner HW, Melton LJ III, et al: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1994;311:1273-1275
3. Cummings SR, Black DM, Nevitt MC, et al: The study of Osteoporotic Fractures Research Group: Bone density at various sites for prediction of hip fractures. Lancet 1993;341: 72-75
4. Castelo-Branco C: Osteoporosis management: An overview. Drugs Aging 1998;12:25-32
5. Stèpán JJ, Pospínchal J, Presl J, et al: Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women. Bone 1989;10:179-185
6. Epstein O, Kato Y, Dick R, et al: A prospective randomized trial of vitamin D, microcrystalline hydroxyapatite compound (MCHC) and calcium gluconate in the treatment of cortical bone thinning in post-menopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982-36:426-430
7. Castelo-Branco C, Pons F, Gonzalez-Merlo J: Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas 1993;16:133-137
8. Del Río L, Pons F, Huguet M, et al: Anterioposterior versus lateral bone mineral density of spine assessed by dual x-ray absorptiometry. Eur J Nucl Med 1995;22:407-412
9. Castelo-Branco C, Rovira M, Pons F, et al: The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996;23:307-312
10. Castelo-Branco C, Martinez de Osaba MJ, Pons F, et al: The effect of hormone replacement therapy on postmenopausal bone loss. Eur J Obstet Gynecol Reprod Biol 1992;44:131-136
11. Cauley J, Seeley D, Ensrud K, et al: Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122:9-16
12. Melis GB, Cagnacci A, Bruni V, et al: Salmon calcitonin plus intravaginal estriol: An effective treatment for menopause. Maturitas 1996;24:83-90
13. Meschia M, Brincat M, Barbacini P, et al: A clinical trial on the effects of a combination of elcatonin and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993;53:17-20
14. Wimalawansa SJ: Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study. Am J Med 1995;99:36-42
15. Riis B, Thomsen K, Christiansen C: Does calcium supplementation prevent postmenopausal bone loss? N Engl J Med 1987;316:173-176
16. Stevenson JC, Mazzuoli GF, Lindsay R, et al: Postmenopausal bone loss and osteoporosis. In The Climacteric and Beyond. Edited by L Zichella, MI Whitehead, PA van Keep. New Jersey, Parthenon Publishing Group, 1988, pp 125-135
17. Decoulx M, Gilquin B, Alam C: Prescription of a microcrystalline hydroxyapatite complex (MCHC) in 30 patients with senile osteoporosis. NPN Med 1983;55:1016-1018
18. Chavassieux P, Pastoureau P, Boivin G, et al: Effects of ossein-hydroxyapatite compound on ewe bone remodeling: Biochemical and histomorphometric study. Clin Rheumatol 1991;10:269-273
19. Ruegsegger P, Keller A, Dambacher MA: Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 1995;5:30-34
20. Ringe JD, Keller A: Osteoporoserisiko bei langzeitiger Heparintherapie thromboembolischer Erkrankungen in der Schwangerschaft: Praventionsversucht mit Ossein-Hydroxyapatit. Geburtshilfe Frauenheilkd 1992;52:426-429
21. Stellon A, Davies A, Webb A, et al: Microcrystalline hydroxyapatite compound in the prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med 1985;61:791-796
22. Lugli R, Brunetti G, Salvioli G: Effect of ossein hydroxyapatite compound on back pain in the elderly: Results of a placebo-controlled trial. Clin Trials J 1990;27:141-145
23. Castelo-Branco C, Martínez de Osaba MJ, Pons F, et al: Coadjuvant use of ossein-hydroxyapatite compounds in subjects on hormone replacement therapy for prevention of postmenopausal bone loss. J Reprod Med 1999;44:241-246